NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

Phase 1

Recruiting

Conditions: Idiopathic CD4 Lymphopenia

Interventions: Drug: Recombinant human interleukin (IL) 7-hyFc

First Posted Date: 2022-11-01

Last Posted Date: 2024-12-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT05600920

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Early Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease
CGD

Interventions: Biological: JSP191

First Posted Date: 2022-11-01

Last Posted Date: 2024-10-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT05600907

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety of Intravenous Apramycin in Adults

Phase 1

Completed

Conditions: Bacterial Infection

Interventions: Drug: Apramycin (EBL-1003)

First Posted Date: 2022-10-21

Last Posted Date: 2024-12-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT05590728

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC - Knoxville, Knoxville, Tennessee, United States

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

Phase 1

Recruiting

Conditions: Rifampicin Resistant Tuberculosis
Tuberculosis

Interventions: Drug: Pretomanid
Drug: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB

First Posted Date: 2022-10-19

Last Posted Date: 2024-02-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT05586230

Locations: 🇮🇳
Site 31441, BJMC CRS, Pune, India
🇿🇦
Site 31976, PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa
🇧🇷
Site 5071, Instituto de Puericultura e Pediatria Martagao Gesteira CRS, Rio De Janeiro, Brazil

and more 4 locations

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Phase 2

Recruiting

Conditions: HIV-1 Infection
Multi-Drug Resistant Hiv-1 Infection

Interventions: Biological: UB-421

First Posted Date: 2022-10-17

Last Posted Date: 2024-10-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT05582694

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Phase 1

Recruiting

Conditions: Herpes Zoster

Interventions: Biological: Shingrix

First Posted Date: 2022-10-14

Last Posted Date: 2024-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 225

Registration Number: NCT05580458

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Siplizumab in T1DM

Phase 1

Active, not recruiting

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Siplizumab

First Posted Date: 2022-10-10

Last Posted Date: 2024-08-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT05574335

Locations: 🇺🇸
Stanford School of Medicine: Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Stanford, California, United States
🇺🇸
Emory University School of Medicine: Emory & Children's Pediatric Research Center, Division of Endocrinology & Diabetes, Atlanta, Georgia, United States
🇺🇸
The University of Chicago: Duchossois Center for Academic Medicine-Hyde Park, Chicago, Illinois, United States

and more 16 locations

Tecovirimat for Treatment of Monkeypox Virus

Phase 2

Completed

Conditions: Monkeypox

Interventions: Drug: Tecovirimat Oral Capsule
Drug: Placebo

First Posted Date: 2022-09-29

Last Posted Date: 2024-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 597

Registration Number: NCT05559099

Locations: 🇨🇩
L'Hôpital Général de Référence de Kole, Kole, Congo, The Democratic Republic of the
🇨🇩
L'Hôpital Général de Référence de Tunda, Tunda, Congo, The Democratic Republic of the

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Phase 2

Recruiting

Conditions: Hepatitis B
HIV Infections

Interventions: Drug: Selgantolimod
Drug: Placebo

First Posted Date: 2022-09-22

Last Posted Date: 2024-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT05551273

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
UCSD Antiviral Research Center CRS, San Diego, California, United States
🇺🇸
University of California, San Francisco HIV/AIDS CRS (801), San Francisco, California, United States

and more 36 locations

Study of Tecovirimat for Human Mpox Virus

Phase 3

Active, not recruiting

Conditions: MPOX

Interventions: Drug: Tecovirimat Oral Capsule
Drug: Placebo
Drug: Tecovirimat Oral Capsule (Open Label)

First Posted Date: 2022-09-10

Last Posted Date: 2024-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 719

Registration Number: NCT05534984

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Los Angeles LGBT Center CRS, Los Angeles, California, United States

and more 57 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy